A live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccine
about
HSV-2: in pursuit of a vaccineInfectious co-factors in HIV-1 transmission herpes simplex virus type-2 and HIV-1: new insights and interventionsInduction of a robust immunity response against novel duck reovirus in ducklings using a subunit vaccine of sigma C proteinA herpes simplex virus 2 (HSV-2) glycoprotein D-expressing nonreplicating dominant-negative HSV-2 virus vaccine is superior to a gD2 subunit vaccine against HSV-2 genital infection in guinea pigsThe murine intravaginal HSV-2 challenge model for investigation of DNA vaccines.Current status and prospects for development of an HSV vaccineBlocking herpes simplex virus 2 glycoprotein E immune evasion as an approach to enhance efficacy of a trivalent subunit antigen vaccine for genital herpes.Pan-HSV-2 IgG antibody in vaccinated mice and guinea pigs correlates with protection against herpes simplex virus 2.A single intramuscular vaccination of mice with the HSV-1 VC2 virus with mutations in the glycoprotein K and the membrane protein UL20 confers full protection against lethal intravaginal challenge with virulent HSV-1 and HSV-2 strains.Immunogenicity and efficacy of intramuscular replication-defective and subunit vaccines against herpes simplex virus type 2 in the mouse genital modelA Highly Efficacious Herpes Simplex Virus 1 Vaccine Blocks Viral Pathogenesis and Prevents Corneal Immunopathology via Humoral ImmunityA novel DNA vaccine technology conveying protection against a lethal herpes simplex viral challenge in miceHerpes simplex virus 2 (HSV-2) infected cell proteins are among the most dominant antigens of a live-attenuated HSV-2 vaccine.Activation of NF-κB in CD8+ dendritic cells Ex Vivo by the γ134.5 null mutant correlates with immunity against herpes simplex virus 1.Live attenuated herpes simplex virus 2 glycoprotein E deletion mutant as a vaccine candidate defective in neuronal spread.Antibodies Are Required for Complete Vaccine-Induced Protection against Herpes Simplex Virus 2.Future of an "Asymptomatic" T-cell Epitope-Based Therapeutic Herpes Simplex VaccineComparison of the host immune response to herpes simplex virus 1 (HSV-1) and HSV-2 at two different mucosal sites.IFN-α-driven CCL2 production recruits inflammatory monocytes to infection site in mice.A Herpes Simplex Virus 2 (HSV-2) gD Mutant Impaired for Neural Tropism Is Superior to an HSV-2 gD Subunit Vaccine To Protect Animals from Challenge with HSV-2.The challenge of developing a herpes simplex virus 2 vaccine.The immunologic basis for severe neonatal herpes disease and potential strategies for therapeutic intervention.Herpes Simplex Vaccines: Prospects of Live-attenuated HSV Vaccines to Combat Genital and Ocular infections.Griffithsin protects mice from genital herpes by preventing cell-to-cell spreadT-cell immunity to human alphaherpesviruses.Inactivated HSV-2 in MPL/alum adjuvant provides nearly complete protection against genital infection and shedding following long term challenge and rechallenge.Single dose of glycoprotein K (gK)-deleted HSV-1 live-attenuated virus protects mice against lethal vaginal challenge with HSV-1 and HSV-2 and induces lasting T cell memory immune responsesHSV-2 vaccine: current status and insight into factors for developing an efficient vaccine.Immunology in the Clinic Review Series; focus on host responses: T cell responses to herpes simplex viruses.The ongoing pursuit of a prophylactic HSV vaccine.Antigenic breadth: a missing ingredient in HSV-2 subunit vaccines?A novel approach for addressing diseases not yielding to effective vaccination? Immunization by replication-competent controlled virus.The Neonatal Fc Receptor and Complement Fixation Facilitate Prophylactic Vaccine-Mediated Humoral Protection against Viral Infection in the Ocular Mucosa.Maternal Antiviral Immunoglobulin Accumulates in Neural Tissue of Neonates To Prevent HSV Neurological Disease.Impact of Type I Interferon on the Safety and Immunogenicity of an Experimental Live-Attenuated Herpes Simplex Virus 1 Vaccine in Mice.A Herpes Simplex Virus Type 2 Deleted for Glycoprotein D Enables Dendritic Cells to Activate CD4+ and CD8+ T Cells.Development of Recombinant HSV-Based Vaccine Vectors.Preventing neonatal herpes infections through maternal immunization.Antisense Phosphorodiamidate Morpholino Oligomers as Novel Antiviral Compounds.Clinical management of herpes simplex virus infections: past, present, and future
P2860
Q22306291-ADACCAE9-81BD-4D8C-B0C8-93FD4210D291Q26823594-E44C804F-047E-4847-BF76-3A9AD9CDAFE7Q30832016-00DC5FC8-8C07-43D5-B280-5FD4836CB1CFQ33825931-F3CF894D-0052-4322-BE4B-0FB00EFFEDCEQ33856067-5CAC03EF-5419-4AA6-9F6C-1F6D03E719B4Q33931016-6C31912F-0C2E-4B1D-BAB2-2A47FB3BB1CBQ34057952-EA25202F-DF41-41F5-8254-15FE3785FC19Q34350019-6A19EC32-68BA-4CC1-81FE-66C05ADEDFDCQ34414463-B0BD6A08-28F3-4C34-B520-E50BAFECB5D8Q34447379-C8B45258-734F-41CE-AC8E-5495E9F8C671Q34520389-4CFBF1F0-9799-4368-B7F0-735F11CCFB86Q35009410-C8D65C62-C8FB-4072-AB14-5BF41E24A4F2Q35058245-6A2B2A69-A492-4F77-8BCD-D07F81981369Q35665813-8840EB6B-97AC-44FD-A0AC-F4C01A276619Q35867958-2BDF6D63-1FAC-4307-AEFC-B076B7110D4AQ35869527-87D7F433-318D-4812-A954-89A569134C41Q36025675-BB12E095-3CE9-4C9E-910D-F957DB7F5D97Q36155593-29CF61E9-AFB7-465A-A2B8-8196C1B0134EQ36253264-AB38C02C-AB76-4AC3-AD61-51B894329644Q36433844-A5966D47-A11C-4153-81F2-42CC613F87B4Q36671106-2A21E648-1B77-4FC0-80CF-C4E158B96357Q36765590-9BD4B9AB-9BD2-452F-BFC7-9DF66D7E0379Q36824210-762D6A23-7E19-434C-BD4E-47748214CD2DQ36827173-85B8B4D4-783D-4F75-B61F-07E7D6FC11CCQ37107189-EA6B7235-FDAD-4F0E-AFBC-F71ED4EEAA09Q37125722-F84900DF-F805-4D15-B575-8BB71831376EQ37305004-B8A6E0CA-D8C4-406D-98CB-308BFAAD245DQ37611796-6DBA27E8-040B-4013-B7A4-95899DF0EBF1Q37963480-384097FE-7563-41D4-A442-EAB093C98217Q37991272-67D82C1C-AE96-470D-8BBB-0445C96CCC83Q38212516-F70EAF70-2B3F-4167-B16E-05DE363DEFFEQ38353693-16B5140A-BE72-4851-AB6D-61614C86AE02Q38650844-3494AF32-55DE-4383-AC61-0096B517455AQ38692329-B942CAFD-694D-457F-834C-A0F66C4EB4F6Q38998931-A8F31162-5B8C-4ECC-A957-A04B94764A7AQ40067153-FF92E920-A02F-4040-AF2A-7644FC88AA15Q40259646-2E87FEFD-D52B-4129-87BB-1F8799C31C61Q47728707-9165036F-E264-4AEC-A4EE-2530F0F139BAQ53687216-6BF26004-2A88-4F6E-A957-7024B6DDF278Q59133817-792C393C-2AA3-45E8-BCD1-516575781C0E
P2860
A live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccine
description
2011 nî lūn-bûn
@nan
2011 թուականին հրատարակուած գիտական յօդուած
@hyw
2011 թվականին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A live-attenuated HSV-2 ICP0 v ...... glycoprotein D subunit vaccine
@ast
A live-attenuated HSV-2 ICP0 v ...... glycoprotein D subunit vaccine
@en
A live-attenuated HSV-2 ICP0 v ...... glycoprotein D subunit vaccine
@en-gb
A live-attenuated HSV-2 ICP0 v ...... glycoprotein D subunit vaccine
@nl
type
label
A live-attenuated HSV-2 ICP0 v ...... glycoprotein D subunit vaccine
@ast
A live-attenuated HSV-2 ICP0 v ...... glycoprotein D subunit vaccine
@en
A live-attenuated HSV-2 ICP0 v ...... glycoprotein D subunit vaccine
@en-gb
A live-attenuated HSV-2 ICP0 v ...... glycoprotein D subunit vaccine
@nl
altLabel
A Live-Attenuated HSV-2 ICP0− ...... Glycoprotein D Subunit Vaccine
@en
prefLabel
A live-attenuated HSV-2 ICP0 v ...... glycoprotein D subunit vaccine
@ast
A live-attenuated HSV-2 ICP0 v ...... glycoprotein D subunit vaccine
@en
A live-attenuated HSV-2 ICP0 v ...... glycoprotein D subunit vaccine
@en-gb
A live-attenuated HSV-2 ICP0 v ...... glycoprotein D subunit vaccine
@nl
P2093
P2860
P1433
P1476
A live-attenuated HSV-2 ICP0 v ...... glycoprotein D subunit vaccine
@en
P2093
Brandon Rakowski
Ringo Püschel
Svetlana Gershburg
William P Halford
P2860
P304
P356
10.1371/JOURNAL.PONE.0017748
P407
P577
2011-01-01T00:00:00Z